Actinium Pharmaceuticals, Inc. (ATNM) 股票分析

公司概述

Actinium Pharmaceuticals, Inc. focuses on developing antibody radiation conjugates and targeted radiotherapies designed to enhance clinical outcomes for patients who have exhausted existing oncology treatment options. The company operates within the Healthcare sector, specifically in the Biotechnology industry, which typically involves high capital expenditure and long development cycles before commercialization. As of the latest data, Actinium holds a market capitalization of $35.77M, generates annual revenue of $90,000, and employs a workforce of 25 individuals. These financial figures indicate that the company is a micro-cap entity with minimal current revenue generation, suggesting it is likely in an early-stage development phase where value is derived primarily from intellectual property and clinical pipeline progress rather than operational cash flow. The extremely low revenue relative to the market cap highlights the speculative nature of its valuation, where the market price reflects potential future commercial success rather than current financial performance.

财务健康

The company reported a trailing twelve-month revenue of $90,000 alongside a net income of -$33,887,000 and an EBITDA of -$36,064,000, revealing a significant structural gap where operating costs and research expenses far exceed any revenue generated. This substantial disparity between negligible revenue and deep net losses demonstrates that the company's cost structure is heavily weighted toward R&D and clinical trial expenses typical for biotechnology firms in the pre-commercial stage. Free cash flow stands at -$12,849,375, indicating a continuous burn rate that relies entirely on external capital sources to fund operations and development activities. The gross margin is reported at 100.0%, while the operating margin is -40274.4% and the profit margin is 0.0%, illustrating that while the cost of goods sold is negligible relative to sales, the overall operational expenses are so high that they result in negative profitability across all standard margin metrics. The balance sheet shows $48.00M in cash against $1.69M in debt, resulting in a debt-to-equity ratio of 21.62, which suggests a conservative leverage profile given the minimal debt load relative to available liquidity. A current ratio of 6.20 further confirms strong short-term liquidity, as the company holds significantly more current assets than current liabilities, providing ample room to cover immediate obligations. Return on Equity is -167.0% and Return on Assets is -35.2%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic of early-stage biotech companies before product approval.

估值评估

Actinium does not have a trailing P/E ratio as earnings are negative, while the forward P/E is listed as -2.02, implying that the market does not currently price in positive earnings growth but rather expects continued losses or a long path to profitability. The price-to-book ratio stands at 4.54, indicating that the market values the company at a significant premium over its book value, likely reflecting the potential value of its clinical-stage product candidates and intellectual property. Price-to-sales is an extremely high 397.42, and the EV/EBITDA is 0.30, suggesting that traditional valuation multiples are distorted by the lack of profitability and that the company's enterprise value is priced primarily on future revenue potential rather than current earnings power. The 52-week high is $1.95 and the 52-week low is $0.95, meaning the current trading price sits within a range that reflects high volatility and speculative trading activity common in small-cap biotechnology stocks. With a beta of -0.21, the stock exhibits a negative correlation to the broader market, meaning it tends to move inversely to the overall market index, which presents a unique but unpredictable risk profile for investors seeking diversification.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A due to the lack of historical data for comparison, preventing a calculation of whether earnings are growing faster or slower than revenue at this specific moment. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash reserves are reinvested directly into research and development to advance its product candidates. This reinvestment strategy is standard for biotechnology firms that must fund clinical trials and regulatory submissions to bring therapies to market before they can generate commercial income. Consequently, the overall growth and income profile of Actinium Pharmaceuticals is characterized by zero current income distribution and a reliance on external financing to sustain high growth efforts in its targeted radiotherapy pipeline.